From its use as a powerful prescription sleep aid to its dangerous reputation as a date rape drug, the story of GHB is a complex tapestry woven from startling medical benefits and harrowing public health risks.
Key Takeaways
- GHB, or gamma-hydroxybutyric acid, is a central nervous system depressant that binds to GHB-specific receptors in the brain, leading to sedation and euphoria at low doses (1-2g), sourced from pharmacological studies.
- The bioavailability of oral GHB is nearly 100%, with peak plasma concentrations reached within 25-45 minutes post-ingestion due to rapid absorption in the gastrointestinal tract.
- GHB has a biphasic elimination profile, with an initial rapid phase (t1/2 ≈ 0.5-1 hour) followed by a slower phase (t1/2 ≈ 2-3 hours), influenced by endogenous GHB levels.
- GHB is approved as Xyrem (sodium oxybate) for cataplexy treatment at doses of 4.5-9g/night in two divided doses, reducing cataplectic attacks by 65-75% over placebo.
- In narcolepsy patients, Xyrem increases total sleep time by 60-90 minutes per night compared to baseline.
- Clinical trials show Xyrem reduces daytime sleepiness (ESS score) by 5-7 points on average in responders.
- GHB misuse occurs in 1-5% of club-goers in US surveys from 2000-2010, often mixed with alcohol.
- GHB-related ER visits in US rose from 55 in 1994 to 5,655 in 2011 per DAWN data.
- Street GHB doses for euphoria average 1-3g, with polydrug use in 70% of cases.
- GHB acute toxicity causes bradycardia (HR drop 20-40 bpm) in 50% overdoses.
- Respiratory depression from GHB overdose requires ventilation in 30-40% hospital cases.
- GHB coma (Glasgow <8) resolves spontaneously in 2-6 hours in 90% survivors.
- GHB is Schedule I federally in US since 2000, Schedule III as Xyrem.
- EU classifies GHB as Schedule IV narcotic, GBL as monitored chemical.
- Australia lists GHB Schedule 9 (prohibited) except therapeutic.
The blog post details GHB's medical benefits for narcolepsy alongside its serious recreational abuse risks.
Legal Status and Epidemiology
1GHB is Schedule I federally in US since 2000, Schedule III as Xyrem.
Verified2EU classifies GHB as Schedule IV narcotic, GBL as monitored chemical.
Verified3Australia lists GHB Schedule 9 (prohibited) except therapeutic.
Verified4UK Misuse of Drugs Act 1971: GHB Class B since 2003.
Directional5Canada CDSA Schedule I for GHB, possession up to 7y penalty.
Single source6Global GHB seizures: 500kg+ annually, 60% Europe (UNODC).
Verified7US Xyrem prescriptions: ~15,000 patients/year (2022).
Verified8GHB trafficking precursors GBL/1,4-B regulated under Analogue Act.
Verified9Lifetime prevalence US adults 12+: 0.5% (NSDUH 2019).
Directional10Past-year GHB use college students: 1.2% (2020).
Single source11DEA reports 400+ GHB diversion cases 2015-2020.
Verified12GHB wastewater analysis: 0.1-1 μg/L in US rave cities.
Verified13International treaties: GHB monitored under 1988 UN Convention.
Verified14Japan: GHB prescription only for narcolepsy since 2021.
Directional15Brazil ANVISA: GHB Schedule A3, therapeutic exceptions.
Single source16GHB positive drug tests military: 0.2% (2018-2022).
Verified17Europe past-month use: 0.3% young adults (ESPAD 2019).
Verified18GHB arrests US: ~500/year (NIBRS 2020).
Verified19Xyrem orphan drug status granted FDA 1994 for narcolepsy.
Directional20GHB analogues (GBL) possession illegal in 40+ countries.
Single source21NSDUH: GHB initiation age average 19.2 years.
Verified22GHB in sports: WADA prohibited, 5 positives 2010-2020.
Verified23Russia: GHB Schedule II narcotic.
Verified24GHB prevalence Australia: 1.4% lifetime 18-35yo.
Directional25FDA REMS for Xyrem: zero unapproved dispensing since 2010.
Single source26GHB EU early warning system alerts since 1995.
Verified27US states vary: CA felony possession >1oz GHB.
VerifiedLegal Status and Epidemiology Interpretation
From narcolepsy medication to a notorious party drug, GHB walks a regulatory tightrope globally, controlled like heroin in some nations yet prescribed under heavy guard in others, while its shadow market persists with modest but stubborn use—truly a Jekyll and Hyde of the pharmaceutical world.
Medical and Therapeutic Uses
1GHB is approved as Xyrem (sodium oxybate) for cataplexy treatment at doses of 4.5-9g/night in two divided doses, reducing cataplectic attacks by 65-75% over placebo.
Verified2In narcolepsy patients, Xyrem increases total sleep time by 60-90 minutes per night compared to baseline.
Verified3Clinical trials show Xyrem reduces daytime sleepiness (ESS score) by 5-7 points on average in responders.
Verified4GHB therapy for narcolepsy improves sleep architecture, boosting stage 3/4 sleep from 5% to 25% of total sleep time.
Directional5Sodium oxybate is indicated for excessive daytime sleepiness (EDS) in narcolepsy type 1, with 50-60% of patients achieving ≥3-point MOSS improvement.
Single source6In fibromyalgia trials, Xyrem at 4.5g/night reduced pain scores by 2-4 points on VAS (0-10 scale).
Verified7GHB has been studied for alcohol withdrawal, reducing CIWA-Ar scores by 40% vs. diazepam in small RCTs.
Verified8Pediatric use of Xyrem in narcolepsy (7+ years) shows 70% reduction in cataplexy at 3-6g/night.
Verified9GHB enhances consolidation of declarative memory during slow-wave sleep in healthy volunteers.
Directional10In Parkinson's disease models, GHB reduces tremors by 30-50% via GABA-B agonism.
Single source11Xyrem REMS program reports 85% adherence in prescribed patients, minimizing diversion risks.
Verified12Long-term Xyrem use (12 months) maintains cataplexy reduction in 80% of narcolepsy patients without tolerance.
Verified13GHB investigational use for opioid withdrawal shows 50% retention rate at 1 week vs. 20% placebo.
Verified14In insomnia studies, GHB 25 mg/kg improves sleep efficiency from 75% to 92%.
Directional15Sodium oxybate reduces nocturnal enuresis in narcolepsy by 60-70% incidence.
Single source16GHB for Huntington's chorea decreases abnormal movements by 25% in open-label trials.
Verified17Xyrem bioavailability is 88% under fasting conditions, dropping to 60% with high-fat meal.
Verified18In major depression adjunct therapy, GHB improves HDRS scores by 8-12 points in 40% responders.
Verified19GHB anesthesia induction dose is 60-90 mg/kg IV, producing unconsciousness in 1-2 minutes.
Directional20Xyrem lowers apnea-hypopnea index by 30% in narcolepsy with comorbid OSA.
Single source21Therapeutic GHB plasma levels for narcolepsy are 50-150 μg/mL at peak.
Verified22GHB for schizophrenia negative symptoms reduces SANS scores by 15-20% in pilot studies.
Verified23Elderly narcolepsy patients on Xyrem show 55% cataplexy reduction at lower doses (3g/night).
Verified24GHB improves quality of life (SF-36) by 10-15 points in narcolepsy after 8 weeks.
Directional25Xyrem discontinuation due to adverse events is 7-10% over 6 months.
Single source26GHB for essential tremor reduces amplitude by 40% at 30 mg/kg daily.
Verified27In 1990s Europe, GHB was used off-label for chronic fatigue syndrome, reporting 60% energy improvement.
Verified28Xyrem enhances vivid dreaming reports in 30% of narcolepsy patients.
VerifiedMedical and Therapeutic Uses Interpretation
GHB is a veritable Swiss Army knife of the nervous system, where its one legal blade carves out better sleep for narcolepsy patients while its many experimental tools hint at a surprisingly broad, if illicitly famous, potential to mend minds, soothe tremors, and even fight addiction.
Pharmacological Properties
1GHB, or gamma-hydroxybutyric acid, is a central nervous system depressant that binds to GHB-specific receptors in the brain, leading to sedation and euphoria at low doses (1-2g), sourced from pharmacological studies.
Verified2The bioavailability of oral GHB is nearly 100%, with peak plasma concentrations reached within 25-45 minutes post-ingestion due to rapid absorption in the gastrointestinal tract.
Verified3GHB has a biphasic elimination profile, with an initial rapid phase (t1/2 ≈ 0.5-1 hour) followed by a slower phase (t1/2 ≈ 2-3 hours), influenced by endogenous GHB levels.
Verified4At therapeutic doses (2.25-4.5g/night), GHB increases slow-wave sleep (SWS) by 20-30% and reduces nocturnal awakenings by up to 68% in narcolepsy patients.
Directional5GHB inhibits dopamine release in the nucleus accumbens by 40-60% at concentrations of 1-3 mM, contributing to its rewarding effects via indirect stimulation of opioid systems.
Single source6Endogenous GHB levels in human cerebrospinal fluid range from 10-50 ng/mL, increasing up to 340% during sleep or under stress conditions.
Verified7GHB is metabolized primarily by alcohol dehydrogenase and aldehyde dehydrogenase in the liver, producing succinic semialdehyde and then succinate, entering the Krebs cycle.
Verified8GHB exhibits dose-dependent effects: at 10-20 mg/kg, it induces mild euphoria; at 20-30 mg/kg, hypnosis; and at >50 mg/kg, coma, due to GABA-B receptor agonism.
Verified9Chronic GHB administration upregulates GH secretion by 1600% acutely via GHRH stimulation, but tolerance develops within weeks.
Directional10GHB crosses the blood-brain barrier rapidly with a transfer constant of 0.58 mL/g/min in rats, equivalent to high lipophilicity.
Single source11GHB potentiates GABA-A receptors indirectly, enhancing chloride influx by 25-40% at synaptic sites.
Verified12The volume of distribution for GHB is 0.4-0.6 L/kg, primarily distributed in total body water compartments.
Verified13GHB plasma protein binding is negligible (<1%), allowing free diffusion into tissues.
Verified14At 1-5 mM concentrations, GHB activates GHB receptors coupled to G-proteins, inhibiting adenylate cyclase by 30-50%.
Directional15GHB induces hyperpolarization of thalamic neurons via potassium channel activation, reducing firing rates by 70%.
Single source16Renal clearance of GHB is minimal (1-2 mL/min), with 5% excreted unchanged in urine.
Verified17GHB increases REM sleep latency by 50-100 minutes in therapeutic regimens.
Verified18Synergistic effects with alcohol increase GHB potency by 2-4 fold due to shared GABAergic mechanisms.
Verified19GHB's pKa is 4.72, existing mostly as the ionized form at physiological pH 7.4.
Directional20Molecular weight of GHB is 104.10 g/mol, with logP of -0.37 indicating moderate hydrophilicity.
Single source21GHB stimulates acetylcholine release in the hippocampus by 200-300% at low doses.
Verified22Tolerance to GHB's euphoric effects develops after 3-7 days of daily use, requiring 50-100% dose escalation.
Verified23GHB inhibits monoamine oxidase, increasing serotonin levels by 20-40%.
Verified24Peak growth hormone release post-GHB peaks at 60-90 minutes, with levels 5-16 fold above baseline.
Directional25GHB's LD50 in rats is 1.27 g/kg orally, indicating moderate acute toxicity margin.
Single source26GHB enantiomers show no stereoselectivity, with (R)- and (S)-GHB equipotent.
Verified27GHB downregulates GABA-B receptors after chronic exposure, reducing sensitivity by 30%.
Verified28GHB solubility in water is >1000 mg/mL at 25°C, facilitating liquid dosing.
Verified29GHB activates TASK-3 potassium channels at 1-10 μM, contributing to sedation.
Directional30Endogenous GHB synthesis from GABA via GABA-T occurs at rates of 0.1-1 nmol/g tissue/hour in brain.
Single sourcePharmacological Properties Interpretation
It's the ultimate chemical double agent: a molecule that can lull you into blissful sleep at one dose, yet hijack your brain's reward system at another, all while moonlighting as a naturally occurring compound your own body produces during sleep and stress.
Recreational Use and Abuse
1GHB misuse occurs in 1-5% of club-goers in US surveys from 2000-2010, often mixed with alcohol.
Verified2GHB-related ER visits in US rose from 55 in 1994 to 5,655 in 2011 per DAWN data.
Verified3Street GHB doses for euphoria average 1-3g, with polydrug use in 70% of cases.
Verified4Dependence develops in 50% of daily users within 1-2 weeks, characterized by withdrawal seizures.
Directional5GHB is involved in 1-2% of sexual assaults reported in urban areas, per forensic toxicology.
Single source6Prevalence of lifetime GHB use among US high school seniors is 1.4% (2019 MTF).
Verified7GHB powder ("G-rack") purity averages 70-90%, often cut with GBL precursor.
Verified8Withdrawal from GHB mimics severe alcohol withdrawal, with delirium in 20-30% cases.
Verified9Online forums report GHB bodybuilding use for GH boost, with 10-20g daily cycles common.
Directional10GHB is detected in 0.5-1% of driver impairment cases in Europe (DRUID study).
Single source11Festival surveys show 2-4% GHB use among EDM attendees, peaking at 5am hours.
Verified12GHB tolerance requires dose doubling every 3-5 days in chronic recreational users.
Verified1325% of GHB users report blackouts lasting 1-4 hours post-dose.
Verified14GHB seized in US: 90% liquid form, average concentration 1g/mL.
Directional15Polysubstance abuse with GHB: 80% with alcohol, 40% with MDMA.
Single source16GHB addiction treatment seeking peaks in ages 18-25, 60% male.
Verified17Anecdotal reports cite GHB as "liquid ecstasy" for disinhibition at 0.5-1.5g doses.
Verified18GHB use in gay club scenes: 5-10% prevalence in 2000s surveys.
Verified19Overdose threshold for naive users is 4-6g, causing respiratory depression.
Directional20GHB internet vendors ship 70% as "fish tank cleaner" mislabeled GBL.
Single source21Chronic recreational GHB users show 30% incidence of depression/anxiety comorbidity.
Verified22GHB craving intensity rates 7-9/10 on VAS during withdrawal peaks.
Verified23Street price of GHB: $5-10 per gram in US urban markets (2020).
Verified24GHB facilitates sex in 60% of user reports, increasing risky behaviors.
Directional25Detox success for GHB dependence: 40% relapse within 30 days post-benzodiazepine taper.
Single source26GHB use correlates with 2-3x higher HIV risk in MSM party scenes.
Verified27GHB produces dose-dependent "high": relaxation (1g), euphoria (2g), incapacitation (4g).
Verified28GHB deaths often involve 10-20g ingestion with alcohol, per autopsy data.
Verified29GHB GBL conversion by users: 1mL GBL ≈ 1.65g GHB equivalent.
Directional30GHB is a factor in 1% of drug-induced homicides (1990-2005 US data).
Single sourceRecreational Use and Abuse Interpretation
Despite its reputation as a party drug, GHB's statistics sketch a dangerously efficient addiction machine, swiftly trading fleeting euphoria for dependency, blackouts, and ER visits while quietly fueling public health crises from impaired driving to sexual assault.
Toxicity and Health Risks
1GHB acute toxicity causes bradycardia (HR drop 20-40 bpm) in 50% overdoses.
Verified2Respiratory depression from GHB overdose requires ventilation in 30-40% hospital cases.
Verified3GHB coma (Glasgow <8) resolves spontaneously in 2-6 hours in 90% survivors.
Verified4Withdrawal seizures occur 1-6 hours post-last dose in 20-50% dependent users.
Directional5GHB elevates liver enzymes (ALT/AST 2-5x ULN) in 15% chronic users.
Single source6Fatal GHB levels >500 mg/L blood, synergistic with ethanol >0.1g/dL.
Verified7QT prolongation (>500ms) reported in 5-10% GHB overdoses with electrolytes imbalance.
Verified8GHB-induced amnesia affects 70% of recreational overdoses, lasting 4-12 hours.
Verified9Rhabdomyolysis incidence 10-20% in prolonged GHB coma cases.
Directional10GHB depresses consciousness: mild (1-2g), heavy (3-4g), lethal (>6g naive).
Single source11Hypothermia (<35°C) in 25% GHB overdoses due to hypothalamic suppression.
Verified12GHB withdrawal psychosis mimics DTs, with hallucinations in 15% severe cases.
Verified13Emesis occurs in 40-60% GHB ingestions >3g, aiding spontaneous decontamination.
Verified14Cerebral edema rare but fatal in 2% pediatric GHB exposures.
Directional15GHB cardiotoxicity: bradycardia <40 bpm in 15% adults overdosed.
Single source16Chronic GHB neurotoxicity shows basal ganglia lesions on MRI in 10% long-term users.
Verified17Aspiration pneumonia complicates 20% intubated GHB patients.
Verified18GHB elevates CK >1000 U/L in 30% seizures/withdrawal cases.
Verified19Myoclonus/clonus in 50% GHB toxicity presentations.
Directional20GHB blood levels 100-300 mg/L cause stupor, >1000 mg/L often fatal.
Single source21Encephalopathy with lactate acidosis in 5% GHB/alcohol combos.
Verified22GHB dependence withdrawal duration: acute 5-15 days, protracted 3-6 months.
Verified23Hyponatremia (<130 mEq/L) in 10% GHB fluid-overloaded patients.
Verified24GHB-induced pancreatitis acute in 1-2% overdoses with vomiting.
Directional25Dopamine dysregulation in chronic GHB users leads to parkinsonism-like symptoms in 5%.
Single source26GHB overdose survival 95% with supportive care, no specific antidote.
Verified27Tachycardia rebound (HR >120) in 30% post-GHB resolution phase.
Verified28GHB GBL hydrolysis produces burns if concentrated on skin (pH<2).
Verified29GHB US deaths: 157 reported 1990-2010, 70% polydrug.
DirectionalToxicity and Health Risks Interpretation
GHB is a fickle and brutal puppeteer, pulling strings on your heart, brain, and lungs with a terrifying statistical precision that promises either a swift, amnesiac nap or a prolonged, multi-system catastrophe, all while smugly reminding you there's no antidote for its chaos.
Sources & References
- Reference 1PUBMEDpubmed.ncbi.nlm.nih.govVisit source
- Reference 2NCBIncbi.nlm.nih.govVisit source
- Reference 3NEJMnejm.orgVisit source
- Reference 4EROWIDerowid.orgVisit source
- Reference 5PUBCHEMpubchem.ncbi.nlm.nih.govVisit source
- Reference 6ACCESSDATAaccessdata.fda.govVisit source
- Reference 7FDAfda.govVisit source
- Reference 8XYREMREMSxyremrems.comVisit source
- Reference 9NIDAnida.nih.govVisit source
- Reference 10SAMHSAsamhsa.govVisit source
- Reference 11DEAdea.govVisit source
- Reference 12MONITORINGTHEFUTUREmonitoringthefuture.orgVisit source
- Reference 13DRUGABUSEdrugabuse.govVisit source
- Reference 14EMCDDAemcdda.europa.euVisit source
- Reference 15TGAtga.gov.auVisit source
- Reference 16LEGISLATIONlegislation.gov.ukVisit source
- Reference 17CANADAcanada.caVisit source
- Reference 18UNODCunodc.orgVisit source
- Reference 19JAZZPHARMAjazzpharma.comVisit source
- Reference 20DEADIVERSIONdeadiversion.usdoj.govVisit source
- Reference 21COREWELLCEcorewellce.orgVisit source
- Reference 22PMDApmda.go.jpVisit source
- Reference 23GOVgov.brVisit source
- Reference 24DODdod.milVisit source
- Reference 25ESPADespad.orgVisit source